YN968D1 is a novel and selective inhibitor of vascular endothelial growth factor receptor‐2 tyrosine kinase with potent activity <i>in vitro</i> and <i>in vivo</i>Shu Tian, Liguang Lou|Cancer Science|2011Cited by 519
Preclinical characterization of anlotinib, a highly potent and selective vascular endothelial growth factor receptor‐2 inhibitorChengying Xie, Liguang Lou|Cancer Science|2018Cited by 368
Aberrant intracellular metabolism of T‐ <scp>DM</scp> 1 confers T‐ <scp>DM</scp> 1 resistance in human epidermal growth factor receptor 2‐positive gastric cancer cellsHongbin Wang, Liguang Lou|Cancer Science|2017Cited by 67
Pharmacological characterization of hetrombopag, a novel orally active human thrombopoietin receptor agonistChengying Xie, Liguang Lou|Journal of Cellular and Molecular Medicine|2018Cited by 59
Flumatinib, a selective inhibitor of <scp>BCR</scp>‐<scp>ABL</scp>/<scp>PDGFR</scp>/<scp>KIT</scp>, effectively overcomes drug resistance of certain <scp>KIT</scp> mutantsJie Zhao, Liguang Lou|Cancer Science|2013Cited by 27